Jane Street’s Avidity Biosciences RNAM Stock Holding History

Jane Street’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,500	Closed	-$2.06M	–	12777
2025 Q4	$2.06M	Sell	28,500 -92,000	-76%	-$5.94M	﹤0.01%	4757
2025 Q3	$5.25M	Buy	120,500 +91,400	+314%	+$3.69M	﹤0.01%	3350
2025 Q2	$826K	Buy	29,100 +12,200	+72%	+$364K	﹤0.01%	5980
2025 Q1	$499K	Sell	16,900 -154,500	-90%	-$4.81M	﹤0.01%	6867
2024 Q4	$4.98M	Buy	171,400 +154,100	+891%	+$6.44M	﹤0.01%	2664
2024 Q3	$795K	Buy	17,300 +5,600	+48%	+$243K	﹤0.01%	6327
2024 Q2	$478K	Buy	+11,700	New	+$336K	﹤0.01%	7094
2023 Q1	–	Sell	-38,900	Closed	-$863K	–	9782
2022 Q4	$863K	Buy	+38,900	New	+$580K	﹤0.01%	5209

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Jane Street's RNAM Position: Q1 2026 in Review

Jane Street sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,734 shares — an estimated $341K sold.

Jane Street first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $6.62M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Jane Street reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Jane Street sold 4,734 Avidity Biosciences shares in Q1 2026, an estimated $341K.
Jane Street first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
Jane Street's Avidity Biosciences position peaked at $6.62M in Q2 2024.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.